BR0207572A -
Pharmaceutical formulation, pharmaceutical daily dose of bicalutamide administrable through the mucosa to a patient, solid dispersion of an enteric polymer, and use of an enteric polymer
- Google Patents
Pharmaceutical formulation, pharmaceutical daily dose of bicalutamide administrable through the mucosa to a patient, solid dispersion of an enteric polymer, and use of an enteric polymer
Info
Publication number
BR0207572A
BR0207572ABR0207572-5ABR0207572ABR0207572ABR 0207572 ABR0207572 ABR 0207572ABR 0207572 ABR0207572 ABR 0207572ABR 0207572 ABR0207572 ABR 0207572A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority claimed from PCT/GB2002/000766external-prioritypatent/WO2002067893A2/en
Publication of BR0207572ApublicationCriticalpatent/BR0207572A/en
"FORMULAçãO FARMACêUTICA, DOSE DIáRIA FARMACêUTICA DE BICALUTAMIDA ADMINISTRáVEL ATRAVéS DAS MUCOSAS A UM PACIENTE, DISPERSãO SóLIDA DE UM POLìMERO ENTéRICO, E, USO DE UM POLìMERO ENTéRICO". A invenção atual refere-se a uma formulação farmacêutica compreendendo bicalutamida e um polímero entérico tendo um pK~ a~ de 3 a 6. A invenção também se refere a uma dose diária farmacêutica de bicalutamida fornecida por tal formulação. Adicionalmente, a invenção refere-se ao uso de tal polímero entérico em dispersão sólida com bicalutamida para aumentar a biodisponibilidade da bicalutamida; para reduzir a variação entre pacientes das concentrações de plasma de bicalutamida; ou para o tratamento e/ou redução do risco de câncer da próstata em um paciente."PHARMACEUTICAL FORMULATION, PHARMACEUTICAL DAILY OF ADMINISTRATIVE BICALUTAMIDE THROUGH MUSCLES TO A PATIENT, SOLID DISPERSION OF AN ENTERIC POLYMER". The present invention relates to a pharmaceutical formulation comprising bicalutamide and an enteric polymer having a pK-a ~ of 3 to 6. The invention also relates to a pharmaceutical daily dose of bicalutamide provided by such formulation. Additionally, the invention relates to the use of such enteric polymer in solid dispersion with bicalutamide to increase bicalutamide bioavailability; to reduce patient-to-patient variation in bicalutamide plasma concentrations; or for treating and / or reducing the risk of prostate cancer in a patient.
BR0207572-5A2001-02-272002-02-22
Pharmaceutical formulation, pharmaceutical daily dose of bicalutamide administrable through the mucosa to a patient, solid dispersion of an enteric polymer, and use of an enteric polymer
BR0207572A
(en)
Pharmaceutical formulation, pharmaceutical daily dose of bicalutamide administrable through the mucosa to a patient, solid dispersion of an enteric polymer, and use of an enteric polymer
Pharmaceutical formulation for mucosal administration to a patient, daily pharmaceutical dose, solid dispersion, use of pvp in solid dispersion with 4'-cyano-alpha ', alpha', alpha'-trifluoro-3- (4-fluoro phenylsulfonyl) - 2-hydroxy-2-methylpropiono-m-toluidide, and methods for increasing storage stability, bioavailability of the drug and for reducing the variation in plasma concentrations of 4'-cyano-alpha ', alpha', alpha ' , -trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropion-m-toluidide among patients
Non-aqueous pharmaceutical gel composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid and its use in the manufacture of a medicament for treatment of psoriasis
Attenuated herpes virus, virus strain, dendritic cell, process to produce a cell, pharmaceutical composition, use of a virus, and process to perform gene therapy on a human or animal patient or to treat or prevent a pathogenic infection or cancer to treat animal patient
Preparations for the application of anti-inflammatory agents, especially antiseptics and / or agents that promote healing of wounds in the upper respiratory tract and / or the ear
Pharmaceutical formulation, pharmaceutical dose, solid dispersion of an enteric polymer, methods for treating prostate cancer and / or reducing the risk of prostate cancer in a patient to increase bioavailability and storage stability of 4'-cyan. alpha ', alpha', alpha '-trifluoro-3- (4-fluorophenylsilphonyl) -2-hydroxy-2-methyl propiono-m-toluidide, and for the preparation of a pharmaceutical formulation, and uses of 4'-cyano alpha ', alpha', alpha'-trifluoro-3- (4-fluorophenylsulfonyl-2-hydroxy-2-methylpropiono-m-toluidide and an enteric polymer
Legal Events
Date
Code
Title
Description
B08F
Application fees: dismissal - article 86 of industrial property law
Free format text:
REFERENTE A 5O, 6O E 7O ANUIDADE.
B08K
Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)
Free format text:
REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.